🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age

RecruitingNAAges 65 Years - 75 YearsMaleUniversity of Nottingham
NCT06567665 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Sarcopenia describes the progressive decline of muscle mass and strength with advancing age and is associated with increased frailty and morbidity, however we do not currently have an effective treatment. Protein feeding and exercise is known to increase muscle mass, but aged muscle shows a lower response to these stimuli leading to muscle loss over time. We do know that ingesting leucine, a building block of protein, can overcome this reduced response to protein feeding and exercise leading to increased muscle mass in older people. However, we do not understand when the optimum time to ingest leucine is to maximise muscle mass after exercise in older people. In this study we will examine the effect of feeding leucine after exercise either with a meal or between meals.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male, 65-75 years of age * BMI 18-28 kg/m2 * Non smoker * Not performing regular resistance type exercise * Participant is willing and able to give informed consent for participation in the study Exclusion Criteria: * A BMI \<18 or \>28 kg·m-2 * Active cardiovascular disease: uncontrolled hypertension (BP \> 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event * Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial) * Respiratory disease including pulmonary hypertension or chronic obstructive pulmonary disease (COPD) * Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), inborn/ congenital errors of metabolism (e.g. phenylketonuria (PKU), galactosaemia) * Active inflammatory bowel disease * Acute infection * Acute or chronic renal disease * Malignancy (or history of malignancy with 5 y) * Recent steroid treatment (within 6 mo), or hormone replacement therapy * Coagulopathy * Musculoskeletal or neurological disorders * Known allergies to any of the product ingredients * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance
💊

What it tests

  • Leucine
📍

Where

1 site
University of Nottingham
Nottingham, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy